Modulation of polycystic kidney disease by non-coding RNAs

Area of Science:

• Molecular Biology
• Genetics
• Nephrology

Background:

• MicroRNAs (miRNAs) are small, non-coding RNAs regulating gene expression.
• Dysregulated miRNA activity is linked to the pathogenesis of kidney diseases, including ADPKD.
• Aberrant miRNA expression is observed in both ADPKD models and human samples.

Purpose of the Study:

• To review the impact of miRNAs on autosomal dominant polycystic kidney disease (ADPKD) progression.
• To discuss the therapeutic potential of antisense oligonucleotides (ASOs), specifically anti-miRNA drugs, for ADPKD treatment.

Main Methods:

• Review of existing literature on miRNA function in ADPKD.
• Analysis of gain- and loss-of-function studies in PKD models.
• Evaluation of preclinical data for anti-miRNA therapies.

Main Results:

• The miR-17 family promotes ADPKD by altering cyst metabolism and inhibiting PKD1/PKD2 expression.
• Other miRNAs (e.g., miR-21, miR-193, miR-214) modulate cyst growth via apoptosis, proliferation, and inflammation.
• Development of an anti-miR-17 drug for ADPKD treatment is underway.

Conclusions:

• miRNAs are significant pathogenic regulators in ADPKD progression.
• Anti-miRNA therapies offer a novel treatment strategy for ADPKD patients.